The incidence of depression or self-harm was 8.2 vs 11.7 events/1,000 person-years in the DPP-4i-cohort and 18.2 vs 13.6 events/1,000 person-years in the GLP-1 RA cohort for incretin-based therapies vs sulfonylureas, respectively
10.1681/ASN.2020050679 [DOI] [PMC free article] [PubMed] [Google Scholar] 15
If you want something this salty, Quince is an accessibly priced option
Wegovy costs around $1,350 per month, and Ozempic and Rybelsus are about $998, though savings programs may make this more affordable
Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review
1 The 505(b)(2) Advantage : This pathway offers a 70-90% cost saving over traditional drug development and a much faster path to market with proprietary exclusivity